Florida State University Research Foundation, Inc.

Gpc Biotech, Inc.

Agennix USA Inc.

Other

Forma Therapeutics, Inc.

Forma Tm, LLC

Gpc Biotech Ag

Krishna K Murthi

Robert A Holton

Arthur F Kluge

Ronald J Biediger

Carmen Somoza

Mitsuru Shindo

Feng Liang

Hyeong Baik Kim

P Douglas Boatman

Chase Smith

Nicholas Bockovich

Chris Oalmann

Zhongguo Wang

Siya Ram

Chase C Smith

Jianxing Huang

Jon H Come

Frank Becker

Vivian Berlin

Kollol Pal

Rebecca L Casaubon

Joachim Vogt

Kerrin Hansen

Tilman Brandstetter

Roland Köstler

Gustave Bergnes

The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.

Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors

The present invention provides derivatives of squaric acid, in particular derivatives of 3,4-diamino-cyclobut-3-ene-1,2-dione and tautomers and isomers thereof, as a single stereoisomer or a mixture of stereoisomers, or as a pharmaceutically acceptable salt thereof. These compounds show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.

Derivatives of squaric acid with anti-proliferative activity

The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, untimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.

Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.

The present invention relates to novel compositions of methotrexate-containing heterodimeric probe molecules, also known as chemical inducers of dimerization (CID), useful in three-hybrid assays. The invention further relates to synthesis of said compositions and their intermediates. Another aspect of the invention is a method for using the heterodimeric probe molecules described herein in drug screens to identify potential protein targets to a given ligand, optimize protein-ligand interactions, or identify potential ligands for a given protein target. In certain embodiments, the invention contemplates the synthesis of the following methotrexate-containing heterodimeric probe: 

Synthesis of methotrexate-containing heterodimeric molecules

The synthesis of taxol and other tricyclic and tetracyclic taxanes.

Tricyclic and tetracyclic taxane intermediates

The present invention relates to compositions and methods for inhibiting fungal growth. In particular, the present invention relates to methods for use as anti-fungal agents of inhibitors, and compositions thereof, of fungal GGPTase. The inhibitors of fungal GGPTase may be peptides, peptidomimetics, or non-peptides.

Growing community of inventors

Cambridge, MA, United States of America

Krishna K Murthi